A model for genetic complementation controlling the chromosomal abnormalities and loss of heterozygosity formation in cancer

被引:4
作者
Nestor, A. L.
Hollopeter, S. L.
Matsui, S.-I.
Allison, D.
机构
[1] Univ Toledo, Dept Surg, Toledo, OH 43614 USA
[2] Univ Toledo, Adv Microscopy & Imaging Ctr, Toledo, OH 43614 USA
[3] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA
关键词
D O I
10.1159/000100406
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The relationship between the apparently random chromosomal changes found in aneuploidy and the genetic instability driving the progression of cancer is not clear. We report a test of the hypothesis that aneuploid chromosomal abnormalities might be selected to preserve cell-survival genes during loss of heterozygosity ( LOH) formations which eliminate tumor suppressor genes. The LOHs and structurally abnormal chromosomes present in the aneuploid LoVo ( colon), A549 ( lung), SUIT-2 ( pancreas), and LN-18 ( glioma) cancer cell lines were identified by single nucleotide polymorphisms ( SNPs) and Spectral Karyotyping ( SKY). The Mann-Whitney U and chi square tests were used to evaluate possible differences in chromosome numbers and abnormalities between the cell lines, with two-tailed P values of < 0.01 being considered significant. The cell lines differed significantly in chromosome numbers and frequency of structurally abnormal chromosomes. The SNP analysis revealed that each cell line contained at least a haploid set of somatic chromosomes, consistent with our hypothesis that cell-survival genes are widely scattered throughout the genome. Further, over 90% of the chromosomal abnormalities seemed to be selected, often after LOH formation, for gene-dosage compensation or to provide heterozygosity for specific chromosomal regions. These results suggest that the chromosomal changes of aneuploidy are not random, but may be selected to provide gene-dosage compensation and/or retain functional alleles of cell-survival genes during LOH formation. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:235 / 247
页数:13
相关论文
共 57 条
[1]  
Allison DC, 1998, J SURG ONCOL, V67, P151, DOI 10.1002/(SICI)1096-9098(199803)67:3<151::AID-JSO2>3.0.CO
[2]  
2-8
[3]  
Anderson GR, 2001, CANCER RES, V61, P8274
[4]  
ANNIKO M, 1984, CANCER, V53, P1708, DOI 10.1002/1097-0142(19840415)53:8<1708::AID-CNCR2820530815>3.0.CO
[5]  
2-L
[6]   How many mutations does it take to make a tumor? [J].
Boland, CR ;
Ricciardiello, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :14675-14677
[7]  
Boveri T., 1929, ORIGIN MALIGNANT TUM, V7, P68
[8]  
Boveri T., 1914, Zur Frage der Entstehung Maligner Tumoren
[9]   Mutations of mitotic checkpoint genes in human cancers [J].
Cahill, DP ;
Lengauer, C ;
Yu, J ;
Riggins, GJ ;
Willson, JKV ;
Markowitz, SD ;
Kinzler, KW ;
Vogelstein, B .
NATURE, 1998, 392 (6673) :300-303
[10]   PREDICTION OF RELAPSE OR SURVIVAL IN PATIENTS WITH NODE-NEGATIVE BREAST-CANCER BY DNA FLOW-CYTOMETRY [J].
CLARK, GM ;
DRESSLER, LG ;
OWENS, MA ;
POUNDS, G ;
OLDAKER, T ;
MCGUIRE, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (10) :627-633